These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26274799)

  • 1. Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.
    Rothlisberger JM; Ovbiagele B
    J Comp Eff Res; 2015 Aug; 4(4):377-84. PubMed ID: 26274799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Counting the true cost of antiplatelet therapy for stroke prevention.
    Morton JA; Newton J; Gray CS
    Age Ageing; 2005 May; 34(3):212-4. PubMed ID: 15863405
    [No Abstract]   [Full Text] [Related]  

  • 3. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
    Shah H; Gondek K
    Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
    Chambers M; Hutton J; Gladman J
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
    Matchar DB; Samsa GP; Liu S
    Value Health; 2005; 8(5):572-80. PubMed ID: 16176495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.
    Redman AR; Ryan GJ
    Expert Opin Pharmacother; 2004 Jan; 5(1):117-23. PubMed ID: 14680441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
    Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
    Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Sep; 10(5):331-42. PubMed ID: 22853743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newer antiplatelet therapies in stroke prevention.
    Davis SM; Donnan GA
    Aust Fam Physician; 2001 Feb; 30(2):129-34. PubMed ID: 11280112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
    Sarasin FP; Gaspoz JM; Bounameaux H
    Arch Intern Med; 2000 Oct; 160(18):2773-8. PubMed ID: 11025787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
    Hankey GJ
    Curr Opin Neurol; 2010 Feb; 23(1):65-72. PubMed ID: 19949330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet agents for secondary prevention of ischemic stroke.
    Majid A; Delanty N; Kantor J
    Ann Pharmacother; 2001 Oct; 35(10):1241-7. PubMed ID: 11675854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account.
    Prescrire Int; 2000 Jun; 9(47):82-3. PubMed ID: 11010748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention.
    Wang Y; Chen W; Wang Y
    Curr Cardiol Rep; 2015 Oct; 17(10):89. PubMed ID: 26294261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiplatelet therapy of secondary stroke prevention after ESPS-2 and CAPRIE].
    Alvarez-Sabín J; Montaner-Villalonga J
    Rev Neurol; 1999 Oct 16-31; 29(8):780-4. PubMed ID: 10560115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.